etretinate ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 1116 54350-48-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • etretinate
  • ethyl etrinoate
  • tegison
  • tigasone
An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.
  • Molecular weight: 354.49
  • Formula: C23H30O3
  • CLOGP: 6.82
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 35.53
  • ALOGS: -5.94
  • ROTB: 8

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
35 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 30, 1986 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05BB01 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR SYSTEMIC USE
Retinoids for treatment of psoriasis
FDA CS M0018962 Retinoids
CHEBI has role CHEBI:50176 keratolytic drugs
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents
FDA EPC N0000175607 Retinoid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Psoriasis indication 9014002 DOID:8893
Oral lichen planus off-label use 235049008
Disorder of keratinization off-label use 277905003
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Corneal erosion contraindication 50792001
Corneal opacity contraindication 64634000
Benign intracranial hypertension contraindication 68267002 DOID:11459
Hypertrophy of bone contraindication 203514008 DOID:205
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL
Retinoic acid receptor RXR-gamma Nuclear hormone receptor AGONIST DRUGBANK CHEMBL

External reference:

IDSource
4019511 VUID
N0000147631 NUI
D00316 KEGG_DRUG
4019511 VANDF
4021061 VANDF
C0015137 UMLSCUI
CHEBI:4913 CHEBI
CHEBI:50173 CHEBI
CHEMBL464 ChEMBL_ID
DB00926 DRUGBANK_ID
D005050 MESH_DESCRIPTOR_UI
5282375 PUBCHEM_CID
7599 IUPHAR_LIGAND_ID
4658 INN_ID
65M2UDR9AG UNII
DB00459 DRUGBANK_ID
16818 RXNORM
117161 MMSL
2306 MMSL
4128 MMSL
4711 MMSL
d01256 MMSL
d03836 MMSL
001964 NDDF
004121 NDDF
108912002 SNOMEDCT_US
108914001 SNOMEDCT_US
386937001 SNOMEDCT_US
386938006 SNOMEDCT_US
5284513 PUBCHEM_CID
C0050559 UMLSCUI
D017255 MESH_DESCRIPTOR_UI
5530 INN_ID

Pharmaceutical products:

None